(Q34649076)

3 August 2017

1 reference

title

Alosetron and irritable bowel syndrome (English)

1 reference

3 August 2017

1 reference

irritable bowel syndrome

1 reference

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

28 March 2024

author name string

Sylvie Bradesi

2

1 reference

3 August 2017

Emeran A. Mayer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14596662

28 March 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

3 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/14656566.4.11.2089

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

Expert Opinion on Pharmacotherapy

28 March 2024

published in

1 reference

3 August 2017

4

1 reference

3 August 2017

11

1 reference

3 August 2017

2089-2098

1 reference

5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review

3 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Effect of ondansetron, a 5-HT3 receptor antagonist, on the dynamic association between bulimic behaviors and pain thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

The impact of irritable bowel syndrome on health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Evolving pathophysiologic models of functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Regulation of serotonin release from the intestinal mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

5-HT3 receptors are membrane ion channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Localization of 5-HT3 receptors in the rat brain using [3H]LY278584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Sex and age differences in the pharmacokinetics of alosetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

AGA technical review on irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Group counseling psychotherapy for patients with functional gastrointestinal disorders: development of new measures for symptom severity and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Regulatory role of 5-HT and muscarinic receptor antagonists on the migrating myoelectric complex in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Role of 5-hydroxytryptamine type 3 receptors in rat intestinal fluid and electrolyte secretion induced by cholera and Escherichia coli enterotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Excitation of rat colonic afferent fibres by 5-HT(3) receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Lotronex and the FDA: a fatal erosion of integrity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Ischemic colitis during treatment with alosetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.11.2089

Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

Localisation by autoradiography of neuronal 5-HT3 receptors in the mouse CNS

28 March 2024

13

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

The distribution of specific binding of the 5-HT3 receptor ligand [3H]GR65630 in rat brain using quantitative autoradiography

28 March 2024

14

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

5-HT2 and 5-HT3 receptor subtypes mediate cholera toxin-induced intestinal fluid secretion in the rat

28 March 2024

25

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

Evidence for thoracolumbar spinal cord processing of inflammatory, but not acute colonic pain

28 March 2024

30

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distension

28 March 2024

31

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron)

28 March 2024

34

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

Alosetron does not affect the visceral perception of gastric distension in healthy subjects

28 March 2024

36

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

Allelic Variation of Human Serotonin Transporter Gene Expression

28 March 2024

42

1 reference

https://api.crossref.org/works/10.1517/14656566.4.11.2089

28 March 2024

Identifiers

1 reference

3 August 2017

1 reference